Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Tehran University of Medical Sciences and Health Services (96-04-48-37253)
- License Information
-
More Information
Article History
Received: 18 November 2020
Accepted: 18 January 2021
First Online: 31 January 2021
Compliance with Ethical Standards
:
: There is no conflict of interest regarding this paper.
: This is the first study on sclerotherapy as the treatment of choice for macrocystic lymphangiomas in the middle-eastern and Iranian population. Since we observed another similar study on 8 Indian children in your valuable journal (Doi: ), we presumed these results can be used in the future review articles and systematic reviews alongside the previous ones.
